Lineage Cell Therapeutics, Inc. Announces Resignation of Chase C. Leavitt as General Counsel and Corporate Secretary, Effective April 7, 2021
March 26, 2021 at 05:23 pm EDT
Share
On March 23, 2021, Chase C. Leavitt notified Lineage Cell Therapeutics, Inc. that he would be resigning as General Counsel and Corporate Secretary effective April 7, 2021 to accept a leadership position at another company. Mr. Leavitt's resignation was not the result of any disagreement with Lineage or its Board of Directors or any matter relating to Lineage's operations, policies, or practices.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Companyâs programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
LINEAGE CELL THERAPEUTICS, INC. 
